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Abbreviations and Definitions 
 
Universal Anaesthesia Machine (UAM) 
The anaesthesia workstation manufactured and marketed by Gradian Health Systems that 
makes use of a draw-over vaporiser and a built-in oxygen concentrator. 
 
Draw-over anaesthesia 
An anaesthesia system where carrier gas (room air or medical air enriched with medical grade 
oxygen) used by the patient's spontaneous ventilatory effort is allowed to pass over a volatile 
anaesthetic vapour through a purpose built low resistance vaporiser.  Whilst spontaneous 
ventilation is the most common setting in which this is described, it can also be used during 
positive pressure ventilation.  This system does not use a carbon dioxide absorber.  It will also 
include the group of patients that are rendered apnoeic by either the induction agent or the 
volatile agent itself and require temporary manual support – this makes use of the UAM’s so-
called “push-over” function, where the mechanism of vaporisation is retained despite the lack 
of ventilatory effort.  
 
Standard Plenum System 
An anaesthetic delivery system that (in our hospital) consists of a circle system containing a 
carbon dioxide absorber with soda lime, all the appropriate valves and a (out of circuit) 
plenum vaporiser.  A plenum vaporiser, in contrast to a draw-over vaporiser, is a high 
resistance device that is dependent on positive pressure and performs predictably regardless 
of the mode of ventilation in use. 
 
Spontaneous ventilation 
Patients who are allowed to generate their own fresh gas flow by means of their own intrinsic 
ventilatory efforts.  This will include the group rendered apnoeic that may require temporary 
manual support.   
 
MHRA 
Medicines and Healthcare products Regulatory Agency.  This is an executive agency of the 
Department of Health in the United Kingdom that aims to protect the population it serves by 
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ensuring that medical devices, blood components, supply chain management and training of 
healthcare workers are, amongst other things, of a sufficient standard.   
 
CE Marking 
This is the symbol as depicted here.  It is the abbreviation of French phrase “Conformité 
Européene” which literally means "European Conformity".  It is the mark used by the 
manufacturer to indicate that it meets with legal requirements to permit its sale and 
movement in the European Economic Area.   
 
The CE mark 
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Abstract 
 
Background 
A new appreciation of relevant risks, as well as the increased availability of technologies that 
facilitate the use of regional techniques, have increased the number of patients that are 
allowed to breathe spontaneously during their procedures.  The ever-growing caseload of 
surgical patients in resource poor environments demands an anaesthetic service and 
equipment capable of meeting with these demands. 
 
Methods 
Patients were recruited to receive their general anaesthesia by means of either the Universal 
Anaesthesia Machine (UAM) or the standard plenum system available.  Anaesthesia was 
administered according to a protocol and the consumption of electricity, carrier gases, 
volatile hypnotic agent and carbon dioxide absorbent was measured.  The cost per minute 
was then calculated for each device respectively.   
 
Results  
Our study recruited 50 patients (25 into each group) across several surgical specialties.  We 
found that when calculated as a total South African Rand (ZAR) per minute cost (for our 
centre) the UAM was statistically significantly more expensive (R 0.974/min vs. R 0.459/min, p  
< 0,00001).  We were able to derive equations to predict the cost consumption of the 
respective devices, allowing the use of this data in a wide array of clinical settings.   
 
Conclusion 
Whilst our finding is by no means surprising, it allowed us to produce formulae by which 
individual centres can calculate the implications of each option using the specific costs of the 
various consumables available to them.   
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1.  Introduction 
 
The clearer understanding of aspiration risk as well as the ever-increasing use of regional 
techniques has brought about a greater proportion of patients that are allowed to breathe 
spontaneously during their procedures, in both resource rich and resource poor settings.  
Draw-over vaporisers have, however, become progressively scarcer.  These factors have 
resulted in an increasing number of patients who ventilate spontaneously under general 
anaesthesia provided by means of a plenum system.   
 
The Universal Anaesthesia Machine (UAM) is a draw-over anaesthesia system that was 
developed in a limited-resource setting.  Its manufacturers speculate that its oxygen 
concentrator could render it competitive from a cost-effectiveness perspective when 
compared to a standard plenum system when an anaesthetised patient is allowed to breathe 
spontaneously. 
 
1.1  Literature Review 
Introduction 
This review straddles the disciplines of health economics and clinical anaesthesia.  It 
addresses the cost efficiency of draw-over anaesthesia when compared to anaesthesia 
administered by means of a plenum system and a circle circuit.  The global population of 
surgical patients is extremely diverse and the resources to provide healthcare to these 
patients is just as heterogeneous and unpredictable.   
 
Unfortunately an extreme paucity of literature exists with regard to this topic.  Also, the 
Universal Anaesthesia Machine is a fairly new device and there is even less research 
available on this device.  We thus draw from several topics relevant to this. 
 
A literature search was conducted using Google Scholar and relevant articles were drawn 
from as far as they were relevant and applicable. A wide variety of search keywords were 
used to generate results and these included: UAM, Universal Anaesthesia Machine, draw-
over anaesthesia, cost-efficiency etc. Also the most recent publications were incorporated 
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even when this appears to be very old literature. As pointed out already, the device and 
topic under examination is rarely studied and this rendered literature review very difficult.  
 
Pharmaco-economics is a division of health economics and is the study of the financial costs 
of drugs and clinical effectiveness.  This scientific discipline has facilitated a growing 
awareness of cost-effective medical practice with, at least sometimes, savings for hospital 
budgets.  Cost-effectiveness impacts directly on the delivery of healthcare services and 
technologies as well as the provision of appropriate facilities, as their costs continue to 
escalate while resources are finite. 1 
 
Out of necessity, practitioners in under-resourced systems have resorted to (and refined) 
various techniques and practices that are often regarded as outdated in first-world settings.  
In anaesthetic circles, the classic example of this is the use of draw-over anaesthesia.   
 
When a patient’s ventilation draws ambient air (that may be supplemented by oxygen 
and/or nitrous oxide) over the surface of a volatile anaesthetic agent in a vaporiser, a draw-
over system exists. 
 
In contrast, a plenum system exists when the anaesthesia apparatus delivers a continuous 
flow of fresh pressurised gas that can then be used to deliver minute volume and/or drive 
ventilator bellows. 2, 3  This system is very often used in conjunction with a circle breathing 
system.   
 
A circle breathing system is basically comprised of the following essential components:  
carbon dioxide absorber (a soda lime canister), two unidirectional valves, a fresh gas 
opening, a Y-piece to connect to the patient, a reservoir bag, a relief valve and low-
resistance tubing. 2 
 
These two systems (draw-over and plenum anaesthesia) have developed largely in parallel.  
A draw-over system is simple to assemble and use.  In contrast to a plenum system, the 
vaporiser has a low internal resistance making spontaneous ventilation through the circuit 
feasible.  It is usually lightweight and portable and in further contrast to plenum systems 
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does not require a constant gas supply.  It is therefore better suited to under-resourced 
settings and military or field anaesthesia.  In addition, infection control is simplified - this 
system is inherently a non-rebreathing system, minimizing the problems of contamination 
and the need for disinfection. 3 
 
Most modern anaesthetists have very little exposure (if any) to draw-over systems and this 
may well skew our perceptions of the need for such systems.  Many places in the world, 
where anaesthesia is delivered, do not even have access to compressed oxygen.  Coupled to 
this, modern anaesthesia stations have complex technology (including electronic flow 
meters) that often require oxygen to drive them (e.g. ventilators), thus limiting their 
application outside well-funded centres. 4  This necessitates a broader view of anaesthesia 
and the challenges faced by anaesthetists.   
 
“Supply and Demand” 
Major improvements in the quality and safety of anaesthesia in recent decades have brought 
about the adoption of international standards for safe practice by the World Federation of 
Societies of Anaesthesiologists (WFSA) in 1992.  This, inter alia, has led to a corresponding 
increased requirement for resources.  It has been suggested that even basic requirements 
have not been met in large parts of the world – more than two decades later. 
 
A significant component of this problem is attributable to a gross lack of training.  A 
questionnaire was presented to 97 (out of approximately 350 in total) anaesthetists in public 
and mission practice from Uganda at a refresher course in May, 2006.  Here it was found 
that the majority were undergoing training or had attended a training course of 1-2 years 
duration.  One respondent had been “trained on the job”. 5  Whilst clearly not material to 
the question of our research it does underline the importance of the fact that simple and 
reliable anaesthesia systems should be put in place in these settings.   
 
Anaesthetists that are formally educated are often trained exclusively in techniques based 
on a continuous supply of nitrous oxide and oxygen.  As was outlined above, the apparatus 
for use with nitrous oxide and oxygen is often available but due to lack of supplies of these 
gases, cannot be used. 6 
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One study in Nigerian hospitals found that 44% of respondents reported an occasional lack 
of running water.  Electricity (including generator supplies) was not always available in 80% 
of locations and intravenous fluids were not always available for 30% of patients.  Ten 
percent reported never having oxygen and 25% reported occasionally having to work 
without oxygen. 5 
 
Conditions amenable to surgical correction “abound among the general population of poor 
countries”. 6  It is believed that the main factors limiting delivery of this service are the 
availability of medical expertise and appropriate facilities.   
 
Detailed and accurate statistics reflecting this are obviously virtually impossible to attain but 
in a 2009 systematic review the authors report that an estimated 2 to 3 billion people have 
no access to surgical care.  They also report that surgical conditions account for 11% of total 
lost years of healthy life.  All surgical disciplines are affected but to varying degrees.  The 
World Health Organisation (WHO) defines surgery as an invasive intervention, but does not 
specifically clarify the need or place of anaesthesia. 6  In more recent literature, the Lancet 
Commission on Surgery and global health reaffirmed the finding that nearly 1 in 3 people 
worldwide do not have access to appropriate surgical care. 7  Disorders requiring surgical 
intervention are believed to comprise in the region of 10% (or 4.7 million) of deaths for the 
year 2011, in mid- and low-income countries. In the same paper, Mock et al. call for the 
production and dispersal of, inter alia, low-cost anaesthesia machines.  They estimate that 
costs would amount to approximately $ 3 billion annually to diffuse surgical care such that 
appropriate procedures are available at primary hospitals but point out that a cost-benefit 
ratio of 10:1 could be gleaned from such spending. 8  At the 68th World Health Assembly, 
held on the 26th of May 2015, agenda item 17.1 highlighted the importance of strengthening 
the delivery of essential surgical care and anaesthesia.  They point out that, internationally, 
each year more than 100 million people sustain traumatic injuries, more than 5 million 
people die from accidental and non-accidental trauma, and that 90% of the global burden of 
violence and injury mortality occurs in low- and middle-income countries. 9 
 
The debate has been how to safely and affordably close the gulf between supply and 
demand for anaesthesia in this patient population on a sustainable basis.   
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“Part of the solution or …” 
Considering the above academic predilection to plenum systems and circle circuits and the 
scientific principle to move from the known to the unknown, it is easy to appreciate that 
experts first consider closed systems and their attendant issues:  fresh gas supply, carbon 
dioxide absorbent, complexity of equipment and the need for electricity; all whilst being 
cost-effective.   
 
A closed breathing system is, however, advised against in some texts; identifying the 
interruption of the oxygen supply as the chief danger.  There are further difficulties with 
vaporisation outside the circuit with the use of basal flow rates and similarly, using artificial 
ventilation with the vaporiser in the circuit.  The erratic supply of CO2 absorbent additionally 
complicates the use of this system and adds to its cost when available. 10 
 
The importance of reliable availability of oxygen is clear and even as early as 1983 authors 
suggest a system that makes use of a “continuous flow of air by compressors with or without 
added oxygen, for use with continuous flow type of apparatus”. 11 
 
More sophisticated equipment, unfortunately, requires regular servicing which is often 
difficult and costly due to the large distances that need to be covered for a relatively small 
number of anaesthetic workstations.   
 
Funding of healthcare operations is as fragile as any other part of the system and is often 
interrupted for a variety of reasons.  This mandates that the provision of such a service be as 
cost-effective as possible.   
 
Given the aforementioned unpredictability of oxygen supplies, an anaesthetic apparatus 
designed for the developing world should be economical in its consumption thereof. 10 
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In one publication, authors show that electricity supplies are also frequently interrupted and 
even generator supply is often lost.  Thus, design of an apparatus must take into account 
that electricity may be lost for hours at a time. 10 
 
In the same article, the authors also call for an apparatus that continues to function in the 
complete absence of compressed gases.  Furthermore, they feel that it should be capable of 
providing anaesthesia to patients who are breathing spontaneously and those that have 
been paralysed pharmacologically, necessitating artificial ventilation.   
 
When electricity is available, Ezi-Ashi et al. feel that it would optimally be used to drive an 
oxygen concentrator. 11 
 
Robustness, reliability and servicing 
“Robustness, reliability and minimal servicing requirements are essential; simplicity of design 
is therefore implied”. 12 
The next logical step would then be to describe specifications for a device theoretically 
capable of answering to the requirements described above.   
 
In a two-part 1983 review Ezi-Ashi et al. investigated and discussed the delivery of 
inhalational anaesthesia in developing countries.  In this paper, they conclude that draw-
over anaesthesia is safer in such an environment and that safety is improved by even low 
flows of oxygen.  Also, that the availability of oxygen is facilitated by the provision of reliable 
electricity. 12 
 
The same authors suggest that a compressor for use with a Boyle-type machine should be 
able to generate at least 25 kPa and flows of between 12 and 20 litres per minute. 11 
 
Oxygen concentrators are specifically discussed – even in older literature.  Compressed air is 
usually passed over Zeolite that removes nitrogen and water vapour, leaving approximately 
90% oxygen with the remainder composed of nitrogen and argon. 11 
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Electricity is still, unfortunately, a necessity, being supplied from mains, generator or 
batteries. 12 
 
Several designers and manufacturers have made attempts at producing an anaesthesia 
workstation that meets these requirements (vide infra) but we must first consider the 
inherent safety implications of such a device.   
 
Primum non nocere 
When administered to humans, gases should be free of oil, particulate matter, carbon 
dioxide, carbon monoxide, etc.  This could be obtained by drawing or passing compressed air 
through specially designed filters. 12 
 
Prior to inducing anaesthesia, the Association of Anaesthetists of Great Britain and Ireland 
(AAGBI) recommends that an alternative means of ventilation be immediately available. 13  
Clearly, this responsibility falls on the shoulders of the anaesthetist, and apparatus 
manufacturers cannot necessarily be expected to cater for this eventuality.   
 
In a different section of the same guidelines, the AAGBI places “absolute responsibility for 
product safety on the manufacturers”. 13  Suppliers are also audited on the provision of 
maintenance.  These guidelines also demand that anaesthetists be trained to use the 
equipment. 14, 15  As highlighted before, a deficiency of training of this kind can, in its own 
right, be a significant cause of anaesthesia related morbidity and mortality.   
 
Some authors regard capnography as an essential part of the routine monitoring during 
anaesthesia.  The use of a vapour analyser is also regarded as essential during anaesthesia 
whenever a volatile agent is in use. 16 
 
Even in developed-world literature, authors of safety guidelines recommend that failure of 
the oxygen supply be addressed prior to the surgery and that a plan is in place:  “Check that 
the apparatus is connected to a supply of oxygen and that a reserve supply is available from 
a spare cylinder”. 17  Oxygen failure is not the only problem that clinicians face in austere 
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conditions.  Some areas, by their very nature, predispose to hypoxia, e.g. those at significant 
altitude.  King et al found that supplemental oxygen at an inspired fraction of 0,3 should be 
delivered at altitudes greater than 1 500 meters above sea level.  Failing the availability of 
this, they regard intermittent positive pressure ventilation as necessary. 18  These 2 
requirements remain central to the safety of any device to deliver anaesthesia.   
 
Of course, arguments against draw-over techniques must be presented and relate 
predominantly to the benefits of a circle system.   
 
Minimal and low-flow anaesthesia are certainly superior in terms of the preservation of 
temperature and humidity and the benefits of this are weighed against the potential risks of 
hypoxia and intra-operative awareness. 2 
 
Researchers investigating respiratory function and mucociliary clearance in patients 
receiving desflurane and nitrous oxide, found that these physiological functions are better 
preserved in a low-flow than in a high-flow anaesthesia technique.  This is attributed to the 
appropriately heated and humidified air introduced into the tracheobronchial tree that limits 
the desiccation of secretions and increased mucous retention as well as heat loss.  This is 
believed to cause partial occlusion in bronchioles that have undergone micro-atelectasis.  All 
these sequelae are thus prevented by a system where exhaled gases are returned to the 
patient. 2  Circle systems retain exhaled water vapour and supply heat and water vapour 
from the absorber. 
 
Plenum vaporisers have a constant driving pressure and predictable flow rates.  Thus, they 
are generally more accurate than draw-over vaporisers, in addition to the above benefits.   
 
Arguments against the use of a plenum system relate to the increased complexity 
(particularly the circle system, that most often accompanies it) and accompanying internal 
resistance, subsequently increasing the work of breathing for a spontaneously ventilated 
patient. 2  Draw over systems are also less accurate than plenum vaporisers at flows below 
2-4 L/min or with small tidal volumes. 19 
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Costs 
Some regard the cost of anaesthesia care as having three main components.  Direct costs 
(cost of agents, materials and labour), indirect costs (costs related to the consequences of an 
event) and intangible costs (the costs related to pain and suffering as a result of illness or 
treatment).  The latter 2 costs, however, are clearly difficult if not impossible to quantify. 1 
 
The direct costs may be divided into fixed and variable costs.  Fixed costs are negotiated in 
advance and remain relatively fixed for a particular period.  Some variable costs depend on 
decisions made by clinicians, and this represents an opportunity to save costs. 1 
 
The fixed factors that contribute to the cost of inhaled anaesthetic agents include the 
acquisition cost per millilitre (mL), the volume of vapour produced per mL of liquid and the 
potency of the agent.  The concentration of the agent required may vary (according to age, 
concurrent medications, temperature, etc.) and the depth of anaesthesia required for the 
invasiveness of the surgery being performed. 1 
 
The costs of an inhaled anaesthetic agent can be expressed as the cost per MAC hour, 
defined as administration of the inhaled anaesthetic agent at 1 MAC for one hour.  This is 
calculated from the concentration of gas delivered, its minimum alveolar concentration 
(MAC), fresh gas flow rate, duration of inhaled anaesthetic delivery, molecular weight, cost 
per mL, a factor to account for the molar volume of a gas at 21°C and density. 16  The fresh 
gas flow rate is clearly the only parameter under the control of the anaesthetist. 1 
 
Indirect costs, whilst potentially a source of cost reduction, will not be reviewed here.   
 
One study that compared low-flow anaesthesia (at 600 mL/min) to flows of 4 L/min found a 
65% reduction in the amount of anaesthetic agent (Isoflurane) used.  This just 
mathematically demonstrates a well-accepted concept but suggests that similar cost 
reductions may well be made elsewhere as well. 20 
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Upon procuring medical devices the MHRA recommend that the following costs and issues 
be considered: 
 Device cost and the cost of its installation  
 Maintenance required and the cost thereof 
 The availability of servicing insurance  
 Cost of its consumables 
 Value for money 
 Cost of its disposal 
 
Routine maintenance includes regular cleaning, preparing the device for its use and device 
calibration of the device. 21 
 
We have thus far considered technical requirements of an anaesthetic apparatus for the 
developing world.  We have looked at pros and cons from a safety perspective and briefly 
reviewed the factors influencing the costs of administering anaesthesia in such settings. 
 
Specific Solutions  
“In austere locations, versatility of manpower and equipment are a must.”  This was said in 
reference to the Portable Anaesthesia Complete (PAC) system.  It is used by the Forward 
Surgical Team of the US military and the British armed forces and also makes use of draw-
over technology. 22 
 
Triservice Anaesthetic Apparatus 
Many anaesthetic machines have been developed to answer the needs of the developing 
world.  An addition to this has been the Triservice Anaesthetic Apparatus.  This system 
incorporates a manual inflation system, two identical vaporisers, an oxygen supplementation 
system and an optional mechanical ventilator (that would, however, need compressed gas 
or electricity).  The vaporiser in this system is descendant of the Oxford Miniature Vaporiser 
(OMV) and constructed from stainless steel, normally requiring no maintenance.  The gas 
delivery components (circuitry etc.) is amenable to disinfection, should the need arise.  The 
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oxygen supplementation system was purpose-built for this system and the two lowest flow 
rates were made available, namely 1 L and 4 L per minute.  This, however, could be altered 
mechanically by changing the size of the apertures in the flow regulator.   
 
The apparatus is rather meticulously reviewed but no perspective is provided in terms of its 
cost efficiency.  Investigators in a 1981 article found respiratory rates between 11 and 24 
breaths/minute with tidal volumes between 250 and 1 000 mL.  They conclude that the 
modularity of this device improves its functionality as different components can be arranged 
in different sequences. 3 
 
The Portable Glostavent 
Again, in a 2010 review of the above machine, Tully et al. call for a machine that can deliver 
anaesthesia safely in the absence of electronic monitors whilst using oxygen efficiently or 
not at all available.   
 
In this device, additional oxygen can be delivered by a cylinder or an oxygen concentrator.  
Its reservoir system has been modified in such a way that room air is entrained when the 
patient’s minute volume exceeds the oxygen flow rate.  This is believed to allow for the 
efficient use of oxygen and for effective pre-oxygenation as well as minimising the space 
required for its use (the concentrator is not “on-board”).  It makes use of a low resistance 
Diamedica vaporiser that can be used for both draw-over and continuous flow anaesthesia, 
and a Laerdal or Ambu non-rebreathing valve.  This device can be assembled in less than 2 
minutes. 
 
It has evolved into its current state over 15 years and is intended for use in rural hospitals 
where draw-over anaesthesia represents the standard of care as “… another concern for 
those administering anaesthesia in isolated environments is the difficulty in obtaining 
pressurised oxygen.”  With this apparatus in use, inhalational anaesthesia can be 
administered using room air if the oxygen supply should fail.  It also allows for the use of 
manual assisted ventilation to counter the negative effects of inhalational anaesthesia.  
Patient safety is believed to be improved by the simple design of the apparatus, especially 
where sophisticated monitoring or carbon dioxide absorption systems are not available.   
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The authors of this article make the following claim with regards to the portable Glostavent:  
“In our opinion, therefore, careful clinical observation of a patient anaesthetised using a 
simple draw-over system is likely to be at least as safe as the use of the more complicated 
system that requires monitors which may be inaccurate or non-existent”. 
 
In disaster situations, an apparatus used for the delivery of oxygen should be portable, easy 
to use, be resistant to wear and tear and be easy to service.  It should also be amenable to 
patients of varying sizes and should be able to deliver anaesthesia in the absence of 
pressurized oxygen at a sufficiently high FIO2 to deal with an emergency.  They also call for a 
device that makes economical use of oxygen.   
 
They claim that the portable Glostavent fulfils all these requirements and successfully fills 
the shoes of the Tri-service anaesthetic device. 10 
 
The Glostavent 
The above devices were designed for use in austere conditions. 22  The Glostavent is a device 
that has evolved from its portable predecessor to deliver inhalational anaesthesia in Low or 
Low-Middle Income Countries (LMIC) and has met the World Federation Of Societies of 
Anaesthesiologists (WFSA) performance standard in this regard. 23 
 
It has an oxygen concentrator capable of producing 8 litres per minute oxygen (at 95%) and 
an equal amount of air.  This rendition of the device still makes use of the Diamedica 
vaporiser.  It is capable of functioning in the absence of electricity by means of an 
uninterruptible power supply and battery.  This device, of all those commercially available, 
most closely represents the Universal Anaesthesia Machine (UAM), except that it includes an 
on-board minute volume divider that allows for positive pressure ventilation. 23 
 
The Universal Anaesthesia Machine 
This device was developed as a low-cost anaesthetic machine for poorly resourced countries.  
Its designer and manufacturers claim ease of use and efficient consumption of oxygen in 
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either draw-over or continuous flow modes.  It is the latest addition to the armamentarium 
of the anaesthetist in a resource poor environment. 
 
The UAM combines draw-over and continuous flow systems.  It is capable of working in 
areas without oxygen or electricity supplies.  Its oxygen concentrator avoids the need for 
sourcing compressed oxygen.  It therefore aims to deliver low cost, environmentally friendly 
anaesthesia.  The vaporiser is manufactured by OES Medical (Oxford, UK) and of the low-
resistance draw-over type, available for Isoflurane and Halothane.  It has a built in oxygen 
concentrator and can therefore deliver supplemental oxygen even when piped or cylinder 
oxygen fails or runs out.  Key differences from a standard Boyle’s machine are the oxygen 
concentrator, draw-over vaporiser, bellows and balloon valve. 24 
 
In a 2010 publication, authors in the United Kingdom reported on initial experiences.  They 
anaesthetised 283 patients aged 1 month to 92 years and 4 kg to 92 kg.   
The authors were unable to report any machine fault but unfortunately failed to report on 
its efficiency. 25 
 
This apparatus was evaluated in the UK and was found to be as safe as generally available 
equipment.  It was regarded as being simple and very easy to learn to use.  It was, however, 
found to have certain limitations: 
 In the case of electrical failure a generator would have to drive the oxygen 
concentrator or an alternative oxygen source would have to be available. 
 More volatile anaesthetic agent will need to be consumed 
 Where long periods of manual ventilation are required, it may become tiring. 24 
This apparatus allows a demand flow patient breathing system to receive up to 10 L/min of 
95% oxygen from the concentrator. 4, 25  It incorporates a unique balloon valve that has 
reportedly functioned well over a period of several years in extremes of temperature, dust 
and humidity.  It can accept and use oxygen and nitrous oxide at any pressure and has built 
in oxygen failure alarms.  Its designer and manufacturer claim that it has lower maintenance 
costs. 4 
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Almost most importantly, it is the only CE marked device of this nature designed for the 
developing world. 24 
 
Conclusion  
Several generations of devices have been designed over recent decades in an attempt to 
answer the need for safe, reliable and cost-effective anaesthesia in the developing world.   
 
Gradian Health along with Dr Paul Fenton have come forward with a possible solution and 
claim that the on-board oxygen concentrator is able to offset the additional costs of 
increased volatile agent consumption.   
The researchers felt that this warranted further investigation.  There were no prior studies 
evaluating a draw-over system against a plenum system in a prospective fashion.  Thus, a 
research protocol was developed de novo. 
 
 22 
2.  Hypothesis 
It is hypothesized that the UAM is able to deliver anaesthesia at a comparable cost to a 
plenum system, as it requires no gas supply.  It extracts oxygen from room air by means of a 
built-in oxygen concentrator and uses no carbon dioxide absorbent.) 
 
3.  Methodology 
The primary outcome of the study is a comparison of the total cost (in South African Rand 
per minute) of the two groups based on the costs of consumables at the Groote Schuur 
Hospital in Cape Town, South Africa.  This will allow us to derive and publish equations that 
will allow stakeholders to determine the cost efficiency of various options in the context of 
their own setting.   
 
The secondary outcomes were: 
 Electricity consumed in kWh 
 Volatile agents consumed in mL/min.   
 Oxygen consumed in L/min (for the plenum group only)  
 Medical air consumed in L/min (for the plenum group only) 
 Carbon dioxide absorbent consumed in mL/min (for the plenum group only) 
 
Costs that are identical were omitted: 
 Machines are maintained by salaried in-house technologists.  Specific parts can be 
ordered from the manufacturers when necessary and this cost, should it arise is easy 
to establish.  Gradian offer product support but the costs relating thereto are very 
difficult to estimate as they are location based.   
 Gradian have, thus far, established their workstations as a non-profit organisation 
and charge USA $ 12 000 per unit, which represents cost price.  They provide on-site 
training for technicians upon installation at no additional cost.  They offer a warranty 
on parts for 2 years.  The plenum systems in use are purchased on a tender basis and 
prices are variable. 
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 Circuit replacement and sterilisation is identical in terms of cost as the same circuits 
are used.   
 Humidifiers/filters are used in an identical fashion and are also disregarded.  
 
We applied for ethics approval to the Human Research Ethics Committee and this was 
granted (HREC 613/2013).  Patients were asked to consent based on the relevant ethical 
principles whilst of sound mental health and under no coercion whatsoever.   
We recruited American Society of Anaesthesiologists (ASA) Class 1 and 2 patients between 
the ages of 18 and 75 who were scheduled for elective non-elevated risk surgery.  The 
planned surgical procedure in all instances was amenable to patients that ventilated 
spontaneously through a laryngeal mask airway under general anaesthesia.  
No patients were removed from the study due to surgical complications necessitating the 
escalation of anaesthesia care.   
Specific exclusion criteria were: 
 Patients younger than 18 or older than 75 
 Those classified as ASA 3 or higher 
 Procedures where the patient could not be rendered subjectively comfortable by 
means of morphine and/or local anaesthesia alone. 
 Procedures where positive pressure ventilation was inherently necessary or may 
have become necessary during the course of the procedure.   
 
Two groups were created, 25 patients in each:  one for the UAM and the other for the 
standard system.  Participants were allocated to either one by means of a table of random 
numbers that was created before initiation of the study.  This table was created by means of 
the Excel function “randbetween”. Cells in one column were numbered 1 to 50 and in an 
adjacent column, cells were allocated to either group one or two and subsequently renamed 
“A or B”. Patients were not made aware of which group they were allocated to. 
Unfortunately, clinicians could not be blinded to which machine was in use. This was due to 
the size of the respective devices and the noise that the oxygen concentrator aboard the 
UAM generates.  Thus, a single-blinded study was conducted.  
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Anaesthesia was administered and data collected by means of a predetermined protocol.  
Only minor deviation from this protocol was ever necessary and patient safety or data 
integrity were never compromised (vide infra). 
 
 
CONSORT diagram.  No participants were excluded once enrolled. 
 
 The same Universal Anaesthesia Machine was used for all cases in the “UAM group”.  
Only machines clearly marked “Datex Ohmeda Aespire” was used for the plenum 
group.  The workstations were checked for circuit integrity and safety.  The 
vaporisers were emptied completely by opening the sump and allowing the agent to 
drain into an Isoflurane bottle.  Emptying was regarded as complete when no drops 
fell from the aperture for 10 consecutive seconds.  The Isoflurane bottles were 
weighed using a scale, the figure recorded and then the vaporiser refilled.   
 Once standard ASA monitoring was applied, patients received 0,1 mg/kg of 
morphine.  No participant experienced adverse effects.  The same Datex-Ohmeda 
monitor was used on both anaesthetic workstations and was plugged into the 
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workstation so that its electricity consumption was accounted for by our 
measurement device (an Efergy energy monitoring socket 2.0, commercially 
available).   
 Patients in both groups were pre-oxygenated for 3 minutes. 
o The Plenum group received 3 L/min of oxygen and 1 L/min of air for 3 
minutes.   
o The UAM group received ± 90% oxygen at ± 5 L/min.   
o The difference would not jeopardise data integrity as the UAM did not make 
use of piped oxygen supplies.   
o The initiation of pre-oxygenation was regarded as “Time in”.  The energy 
meter was zeroed at this time and measurement commenced.   
 Anaesthesia was induced with Propofol at approximately 2 mg/kg.  This was titrated 
such that the laryngeal mask airway (LMA) was tolerated.  Where doses beyond this 
were required, no significant additional ventilator support ever became necessary.   
 Once anaesthesia had been induced: 
o The UAM group was maintained at an FIO2 of 0,4 until the conclusion of 
surgery.   
o The Plenum group was allowed another 5 minutes of “wash-in” at the above 
flows.  After this fresh gas flows were turned down to 0,5 L/min each of air 
and oxygen.  Where deviations occurred, they were clearly recorded and 
accounted for during statistical analysis.   
o Anaesthesia was maintained by means of an end-tidal Isoflurane 
concentration of 1% as measured by a gas analyser for both groups. 
o The carbon dioxide absorbent was employed from the initiation of pre-
oxygenation until 3 minutes after the conclusion of surgery or where the LMA 
was no longer tolerated.   
o Where ventilatory support became necessary, a breath was administered 
every 30 seconds.  No patient ever required support beyond the onset of the 
surgery.   
o Where additional analgesia was deemed necessary, morphine was 
administered.  The individual doses were recorded.  The targeted response 
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was unfortunately a subjective one.  If patients were not tachycardic (having 
had hypovolaemia ruled out), not tachypnoeic nor hypertensive (in the 
absence of other causes); they were regarded as pain free.  The 
administration of local anaesthetic agents to the wound was done at the end 
of the procedure and represented (if applicable) the last painful stimulus.  
Considering the fact that patients were allowed to breathe spontaneously and 
subjected to procedures not characterised by large volume shifts, we used 
swab counts, suction bottles and (if catheterised) urine output to monitor the 
loss of volume.   
o Haemodynamic parameters where maintained within autoregulatory limits 
(i.e. a mean arterial blood pressure of more than 65 mmHg) and 20% of 
baseline in hypertensive patients.  This was achieved by means of 
phenylephrine boluses (50 μg) and/or ephedrine (5 mg) boluses.   
 At the conclusion of the surgery: 
o The vaporiser was switched off (both groups). 
o The fresh gas flows were turned up to 3 L/min of air and 1 L/min of oxygen in 
the Plenum group.  Erroneously, some cases were allowed 3 minutes and 
others 5 minutes of washout.  The average duration of washout was 4 
minutes.  Each individual case was recorded separately and the duration of 
the case calculated.  This does not impact on the final cost per minute.   
 At the conclusion of the anaesthetic:  
o The amount of electricity consumed was recorded (both groups), the soda 
lime canister was dropped from the circle circuit and the fresh gas flows 
increased to meet the requirement of the leak in the circuit.  The “time out” 
was recorded at this stage.  This presented a data point when the anaesthetic 
was over and its duration could be calculated.  Data collection had ceased 
prior to high flows necessitated by the circuit leak.  Once the LMA had been 
removed, the flows were closed and the patient transferred to the recovery 
area.   
o The same soda lime canister was used as described until the inspired partial 
pressure of CO2 (PICO2) was 1,0 kPa for 10 minutes.  The amount of absorbent 
was then averaged out over the number of minutes that it took to be 
saturated (calculated from the “time in” and “time out” fields.  The 
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randomisation and participant identification unfortunately necessitated 
periods of time between cases in the Plenum group.  This meant that, to an 
unquantifiable extent, the absorbent was allowed to regenerate.  This will 
almost certainly underestimate the consumption of the absorbent.   
 Once the patient had been handed over to the recovery staff, the vaporiser was 
emptied into the same bottle from which it had been filled.  The bottle was then 
weighed and the figure recorded (both groups).  To quantify the amount of volatile 
that may have spilled and/or vaporised is virtually impossible.   
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4.  Results 
50 Participants were enrolled into one of two groups and subjected to the following surgical 
procedures: 
Procedure UAM Plenum 
General Surgery:   
 Lymph node biopsy 2  
 Incision & drainage abscess 7 5 
 Split skin graft 2  
 Microductectomy 1  
 Excision breast mass  1 
 Rectal biopsy  1 
Orthopaedic Surgery:   
 Wound debridement 1  
 Removal of orthopaedic hardware 1 2 
 Open reduction & internal fixation (ORIF) – Calcaneum 1  
 ORIF – Distal radius fracture 1  
 Metacarpal joint release or ORIF – Finger 1 1 
 Bunion correction  1 
 Orthopaedic open biopsy 2  
 ORIF & bone graft - Tibia  1 
 Multiple nerve transfers  1 
 Percutaneous ORIF – Distal femur   1 
Urology:   
 Transurethral cystoscopy, lithotripsy & stent insertion 1 4 
 Extra-corporeal shock-wave lithotrypsy 2 4 
Gynaecology:   
 Operative hysteroscopy and IUCD insertion 1 3 
 Cervical cone biopsy 2  
Totals 25 25 
 
 Table 1.  Detail of the distribution of procedures between the respective groups. 
 
A fairly heterogeneous group of procedures are thus seen.  This is believed to realistically 
simulate the surgical stimulus that may be encountered in a resource-poor setting, in that 
neurosurgical, thoracic and major intra-abdominal procedures were excluded.  
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 Fig. 1.  Graphic presentation of procedures for which the UAM was used. 
 
 
 
 Fig. 2.  Graphic presentation of procedures for which the plenum system was used. 
 
The demographic and general properties of the 2 groups were as follows:  
Parameter UAM Plenum 
Average age 40,6 years 41,6 years 
Males 12 9 
Females 13 16 
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ASA 1 13 17 
ASA 2 12 8 
Average weight 75,7 kg 76,0 kg 
 Table 2.  Demographic data of the 2 groups 
Parameter UAM Plenum 
Average morphine dose 7,60 mg 7,83 mg 
Average morphine dose per kg 0,101 0,103 
Average duration of surgery  52,0 minutes 61,6 minutes 
                  Table 3.  General data of the 2 groups 
It is seen here then that the 2 groups were sufficiently similar to regard patient factors as 
being controlled for as far as reasonably possible.  The cases in the plenum group were, on 
average, longer and this was accounted for by calculating the cost per minute of 
administering the anaesthetic.   
The cost of consumables at our centre (Groote Schuur Hospital, Anzio Road, Observatory, 
Cape Town, South Africa) are in South African Rand (ZAR): 
Consumable Cost 
Electricity R 0.80 per kWh 
Carrier gas:  Oxygen  R 0.0072 per litre 
Carrier gas:  Air R 0.0072 per litre 
Isoflurane R 216.18 per 250 mL 
Carbon dioxide absorbent (soda lime) R 169.12 per 5 litre container 
 
 Table 3.  Cost of consumables 
 
The statistical analysis was done by means of an electronic package, Statistica Version 12.  
The total cost per anaesthetic was calculated.  The data were subjected to a test for 
normality of distribution and found to be non-parametric in distribution.   
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 Fig. 3.  The non-parametric distribution of the data 
 
 
Data were subjected to a Man-Whitney-U test with continuity correction.  The findings were 
as follows: 
Group Mean Confidence Interval p value 
UAM R 0.974/min  R 0.860/min to R 1.087/min 
< 0,00001 
Plenum R 0.459/min R 0.384/min to R 0.534/min 
 
 Table 4.  Comparative cost of anaesthesia 
 
The finding is thus that a statistically significant difference exists between the 2 groups.   
This is, however, not surprising, and represents only the preliminary part of our question.  
The next part relates to the generation of equations that may allow healthcare managers to 
predict the cost effectiveness of a device of this nature. 
Total Cost per minute for the Plenum System is calculated as follows: 
Volatile Cost + Electricity Cost + Gas Cost + Soda lime Cost 
Duration of Anaesthesia 
 
If this is then expanded upon: 
[(Volatile x 1,496) x (costV ÷ volV)] + [Elect x costE] + [Gas1 x costG1 x Time] + [(0,5076 x Time) x (costS ÷ volS)] 
Time 
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Legend 
 Volatile = Amount of volatile consumed in grams.  If the volume in millilitres (mL) is 
known, the correction factor 1,496 is omitted.   
 costV = Cost per unit as the volatile is issued by the pharmacy.  i.e. cost per bottle 
 volV = Volume of volatile agent as issued by the pharmacy.  i.e. bottle volume in mL 
 Elect = Amount of electricity consumed in kilowatt hour. 
 costE = Cost of electricity as provided by the supplier per kilowatt hour.   
 Gas1 = Averaged fresh gas flow in L/min.  This term needs to be expanded if more 
than one gas is used.  For each additional carrier gas the term: 
(Gas2 x costG2 x Time) 
is included and summed.   
 costG1 = Cost of the gasses (per litre) as provided by the hospital. 
 0,5076 = Consumption (mL) of soda lime per minute from our data. 
Canister volume of 667 mL that lasted 1 314 minutes to reach an inspired fraction 
of carbon dioxide equal to 1 percent (FICO2 of 0,01).   
 PriceS = Purchase price of a container of carbon dioxide absorbent as issued by the 
pharmacy.   
 volS = Volume of carbon dioxide absorbent container as provided by the pharmacy.   
 Time = Duration of the anaesthetic in minutes 
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For a draw-over system, the term relating to carbon dioxide absorbent can be omitted and, 
if only an oxygen concentrator is used the terms relating to fresh gas flow can similarly be 
omitted: 
[(Volatile x 1,496) x (costV ÷ volV)] + [Elect x costE] + [Gas1 x costG1 x Time] 
Draw-over with non-
concentrator Oxygen or 
Nitrous oxide 
Time 
 
[(Volatile x 1,496) x (costV ÷ volV)] + [Elect x costE] Draw-over with only 
concentrator Oxygen Time 
 
Legend: 
 Volatile = Amount of volatile consumed in grams.  If the volume in millilitres (mL) is 
known, the correction factor for grams to millilitres of 1,496 is omitted.   
 costV = Cost per unit as the volatile is issued by the pharmacy.  i.e. cost per bottle 
 volV = Volume of volatile agent as issued by the pharmacy.  i.e. bottle volume in mL 
 Elect = Amount of electricity consumed in kilowatt hour. 
 costE = Cost of electricity as provided by the supplier per kilowatt hour.   
 Gas1 = Averaged fresh gas flow in L/min.  This term needs to be expanded if more 
than one gas is used.  For each additional carrier gas the term: 
(Gas2 x costG2 x Time) 
is included and summed.   
 costG1 = Cost of the gasses (per litre) as provided by the hospital. 
 
 
5.  Shortcomings 
The fairly novel nature of the UAM has meant that there are no prospective data considering 
its cost-efficiency.  This coupled to the fact that the question of cost-efficiency in the context 
of draw-over anaesthesia has never been addressed prospectively has made both literature 
review and protocol development particularly challenging.   
 
The filling of the UAM vaporiser necessitates that volatile agent be poured into it.  This, even 
if no agent is spilt, inherently means that some of the agent vaporises.  The plenum 
vaporiser, in contrast, is almost a sealed system where virtually no vapour is lost during 
filling.  This difference skews data in favour of the plenum system.  We are not aware of a 
sustainable solution to control for this situation and believe that it represents a problem that 
exists when the device is used in clinical practice.   
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The randomisation process unfortunately required that there were periods of time (days) 
between the enrolment of cases in the plenum group.  To avoid the soda lime canister being 
used during non-research cases, it had to be removed and kept away from the theatre 
complex.  This led to the carbon dioxide that had been absorbed being liberated to an 
unquantifiable extent, allowing regeneration of the soda lime.  This would have skewed data 
in favour of the plenum system in that the amount of soda lime consumed was 
underestimated over the total duration of time that it was used.   
 
6.  Conclusion 
We present mathematical relationships that aim to aid responsible persons to predict the 
cost efficiency of the Universal Anaesthesia Machine and a circle system for their particular 
environment.  These equations hope to accommodate factors that influence the acquisition 
price of carrier gas and other consumables.  We are unfortunately not able to account for all 
the relevant costs, as is the case when a workstation has its battery charged and is then used 
or the influence of oil and fuel prices, distances between sites where oxygen is dispensed 
and anaesthesia is delivered etc.  These costs may vary between different health 
environments and our equations hope to allow for these variations.  Costs relating to the 
installation and maintenance of these devices are also highly variable and often determined 
by factors that are extremely difficult to account for.  It is our belief that the safety and 
robustness of draw-over anaesthesia systems will continue to render it a very attractive 
option in a resource-poor setting and the data presented here may well strengthen the 
argument for the acquisition of the appropriate equipment.   
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Addendum: Consent Documentation 
Participant Information Document 
 
The Universal Anaesthesia Machine (UAM) is a newly developed anaesthesia machine, specifically 
designed for patients that breathe on their own during their operations.  
 
The study we aim to conduct is titled: “A cost comparison of spontaneously ventilated patients: the 
UAM as a possible cost effective alternative.” 
 
Our study will compare the costs incurred by the use of the Universal Anaesthesia Machine to the 
costs incurred by the use of a standard anaesthesia machine. We will simply record the amount of 
oxygen, medical air, anaesthetic drugs, electricity and carbon dioxide absorbent used during the 
anaesthetic.  
 
We are planning to pay for our own research.  
 
You will not be paid for if you decide to participate in this study.  
 
The research question was originally suggested by the machine’s manufacturers (Gradian Health). 
That is, however, the extent of their involvement. Neither of the investigators holds any personal 
interest in this company. Therefore, no conflict of interest exists. 
 
The information gathered from this study will hopefully help health managers (particularly in 3rd 
world systems) to buy the most appropriate anaesthetic machines. 
 
There are no particular benefits, harm or additional risks to you as participant. We will use 
anaesthesia machines already in active daily use according to the standard of care at our hospital. All 
the machines in use have been tested, checked and certified as safe.   
 
The University of Cape Town (UCT) undertakes that in the event of you suffering any significant 
deterioration in health or well-being, or from any unexpected sensitivity or toxicity, that is caused by 
your participation in the study, it will provide immediate medical care. UCT has appropriate 
insurance cover to provide prompt payment of compensation for any trial-related injury according to 
the guidelines outlined by the Association of the British Pharmaceutical Industry, ABPI 1991. Broadly-
speaking, the ABPI guidelines recommend that the insured company (UCT), without legal 
commitment, should compensate you without you having to prove that UCT is at fault. An injury is 
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considered trial-related if, and to the extent that, it is caused by study activities. You must notify the 
study doctor immediately of any side effects and/or injuries during the trial, whether they are 
research-related or other related complications. 
UCT reserves the right not to provide compensation if, and to the extent that, your injury came about 
because you chose not to follow the instructions that you were given while you were taking part in 
the study. Your right in law to claim compensation for injury where you prove negligence is not 
affected. Copies of these guidelines are available on request. 
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Consent Document 
 
You can freely choose to participate or not to participate in this study. You will suffer no harm or 
discrimination and will still receive care according to the standard at our facility.  
 
Your participation in this study will not have any influence on the standard of care that you will 
receive, regardless of whether you decide to participate or not.  
 
We will pay for our own research and neither of the researchers hold any interest in the company 
that makes the UAM. There is, therefore, no conflict of interest.  
 
You will not be paid to participate in this study. 
 
If you should decide to consent, you are welcome to withdraw consent before or after your 
operation. You will continue to receive care according to the usual standard of our facility. If you do 
decide to take part, you will not be expected to do or say anything beyond what is expected of any 
other patient.  
 
If you choose to participate, you will be assigned to one of the two groups: either the group where a 
standard machine will be used or the group where the UAM will be used.  
 
We will record your weight, the amount of electricity, pain medication received, anaesthetic drug, 
oxygen, medical air and carbon dioxide absorbent used during your anaesthetic. We will also record 
the duration of your anaesthetic. After your anaesthetic is over, your involvement in the study will 
end.  
 
Should you wish to see the results of the research on your anaesthetic, this information can be made 
available to you. 
 
The University of Cape Town (UCT) undertakes that in the event of you suffering any significant 
deterioration in health or well-being, or from any unexpected sensitivity or toxicity, that is caused by 
your participation in the study, it will provide immediate medical care. UCT has appropriate 
insurance cover to provide prompt payment of compensation for any trial-related injury according to 
the guidelines outlined by the Association of the British Pharmaceutical Industry, ABPI 1991. Broadly-
speaking, the ABPI guidelines recommend that the insured company (UCT), without legal 
commitment, should compensate you without you having to prove that UCT is at fault. An injury is 
considered trial-related if, and to the extent that, it is caused by study activities. You must notify the 
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study doctor immediately of any side effects and/or injuries during the trial, whether they are 
research-related or other related complications. 
UCT reserves the right not to provide compensation if, and to the extent that, your injury came about 
because you chose not to follow the instructions that you were given while you were taking part in 
the study. Your right in law to claim compensation for injury where you prove negligence is not 
affected. Copies of these guidelines are available on request. 
 
If you have any questions or complaints about your welfare or rights as participant, you can contact 
any of the researchers: 
Dr. G.P. van Rensburg: 082 554 1405 or 021 404 5001 
Dr. R.W. Nieuwveld: 021 404 5445 or 021 404 5001 
 
Or the Human Research Ethics Committee: 
Prof. Marc Blockman (Chairman): 021 406 6338 
 
 
 
 
……………………….. 
Participant 
……………………….. 
Investigator 
 
 
